Topic Listing for ARIAD Pharmaceuticals

Accounting Estimates Accounting Officer
Acute Myeloid Leukemia Aml Additional Acts
Additional Data Ash Additional Indemnification Exoneration Rights
Additional Information Concerning Board Directors Committees Additional Insured
Additional Non-oncology Indications Mtor Inhibitor Ap23573 Additional Progress Clinic
Advance Ap24534 Innovative Oncology Pipeline Advance Innovative Oncology Pipeline
Advances Expenses Defense Claim Advances Milestone Global Collaboration Merck Inc
Advancing Clinical Pipeline Adverse Event
Affiliate Affiliates Distributors
Aggregated Option Exercises Last Year-end Values Agti Independent Disinterested Directors
Allowable Instruments Amended Restated Term
Amendment Employment Agreement Angiogenesis Solid Tumors
Annual Performance Awards Annual Report Form 10-k Incorporation Reference
Ap23573 Ap23573 Phase Clinical Data
Ap23573 Phase Clinical Trials Ap24534
Ap24534 Clinical Data Presented Ash Ap24534 Solid Tumors
Applicable Law Consent Jurisdiction Approval Amendment Ariad Pharmaceuticals Inc 1997 Employee Stock
Argent Cell-signaling Regulation Technology Ariad
Ariad Announces 2008 Key Corporate Objectives Plans Development Ariad Announces 2009 Key Corporate Objectives
Ariad Announces Clinical Data Phase Study Investigational Mtor Ariad Announces Court Rulings Regarding Nf-954b Patent Lawsuit
Ariad Announces Favorable Ruling Permitting Immediate Appeal District Ariad Announces Full Enrollment Phase Succeed Trial Evaluating
Ariad Announces Preliminary Data Ongoing Clinical Trials Investigational Ariad Announces Preliminary Results Ongoing Clinical Trial Investigational
Ariad Announces Start Phase Clinical Study Oral Deforolimus Ariad Announces Start Phase Clinical Trial Oral Deforolimus
Ariad Ap23573 Development Program Reports Ariad Appoints Former Bristol-myers Squibb Senior Executive New
Ariad Appoints New Members Board Directors Ariad Appoints Richard Pascoe Chief Operating Officer Expands
Ariad Data Ariad Gene Therapeutics Inc Stock Option Plan
Ariad Initiates Phase Clinical Trial Investigational Oral Multi-targeted Ariad Pharmaceuticals Inc
Ariad Pharmaceuticals Inc Landsdowne Street Cambridge 02139-4234 Ariad Presents Novel Anti-cancer Profile Investigational Anaplastic Lymphoma
Ariad Presents Preclinical Data Deforolimus Bicalutamide Androgen-independent Prostate Ariad Presents Preclinical Data Kinase Inhibitor Ap24534 Demonstrating
Ariad Presents Preclinical Deforolimus Data American Association Cancer Ariad Reports 2008 Financial Results
Ariad Reports 2008 Financial Results Development Progress Ariad Reports 2009 Financial Results Development Progress
Ariad Reports Year-end 2007 Financial Results Ariad Representations
Ariads Obligations Assignment
Assignments Athanase Lavidas Phd
Attached Following Page Audit Committee
Audit Non-audit Fees Authorized Distributor
Authorized Distributors Background
Base Salary Because Members Management Team Board Directors Beneficially Own
Because Not Own Outstanding Stock Subsidiary Ariad Gene Beneficial Ownership Reporting Compliance
Benefits Board Directors
Board Directors Recommends Stockholders Vote Proposal Bona Fide
Bone-targeted Mtor Inhibitor Program Borrowers
Breast Cancer Burton Sobel
Business Strategy Camille Bedrosian
Cardiovascular Indications Mtor Inhibitor Ap23573 Cash Equivalents
Certain Relationships Related Transactions Certain Relationships Related Transactions Director Independence
Certificates Endorsements Certification Pursuant 906 Sarbanes-oxley Act 2002 Subsections 1350
Certifications Cglp
Cgmp Chairman Chief Executive
Chairman President Change Control
Changes Senior Management Team Characterization Oral Formulation
Chief Executive Officer Chief Legal Officer Secretary
Chief Medical Officer Chief Patent Counsel
Chronic Myeloid Leukemia Cml Clinical Data Deforolimus Ap24534 Anticipated Half
Clinical Proof-of Concept Patients Cml Cmc Data
Cml Commercial Sale
Committee Operations Common Stock
Common Stock 001 Par Value Communication Audit Committees
Compensation Committee Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Discussion Analysis
Competing Technologies Render Some Programs Future Products Noncompetitive Competition
Compliance Laws Regulations Condition Results Operations
Conditions Indemnification Confidential Information
Confidentiality Consent Independent Registered Public Accounting Firm
Construction Contact
Continuation Clinical Experience Showing Deforolimus Well-tolerated Continuing Class Directors Term Expire 2009
Contractual Obligations Contribution Event Joint Liability
Controlled Controls Procedures
Corporate Code Conduct Ethics Corporate Governance
Corporate Objectives Corporate Overview
Counterparts Countries
Credit Agreement Critical Accounting Policies Estimates
Cure Period Currency
Daniel Bollag Phd Data Support Genetic Biomarkers Identify Patients Vertical Pathway
David Berstein Esq Deduction Limits
Definitions Deforolimus
Deforolimus Mk-0646 Combination Deforolimus Non-small Cell Lung Cancer Kras Mutation
Departure Directors Certain Officers Election Appointment Compensatory Dependent Ability Medical Device Partner Develop Manufacture Test
Determination Payments Due Develop Product Commercial Subsequent Liability-related Claim Recall Adverse
Development Obligations Development Officer
Director Compensation Director Compensation Arrangements
Director Independence Directors
Directors Executive Officers Corporate Governance Dispute Resolution
Disputes Dividends
Dmf Downgrade Policy
Duration Agreement Earnings Per Share
Edward Fitzgerald Effective Date
Effects Termination Election Class Directors Hold Office Until 2010 Annual
Election Class Directors Hold Office Until 2011 Annual Elements Total Direct Compensation
Elizabeth Wyatt Employee Stock Purchase Plan
Employees Employment Agreements
Employment Agreements Termination Change-in-control Arrangements Employment Termination Without Cause
Employment Terminations Except Death Endometrial Cancer
Enforcement Binding Effect Engagement Ariad
Entire Agreement Equity Compensation Plan Information
Equity Incentives Stock Options Restricted Establishing Quorum
Establishment Establishment Trust
Even Bring Products Market Unable Effectively Price Obtain Except Share Per Data
Exceptions Exclusions
Exclusive Licensees Executive Committee
Executive Compensation Executive Compensation Arrangements
Executive Compensation Plan Executive Officers
Executive Officers Key Employees Exhibits
Explanatory Extension Terms Employment Agreements Named Executive Officers
Facility Lease Fair Value Financial Instruments
Fda Financial Guidance
Financial Guidance 2008 Financial Guidance Update
Financial Highlights Financial Information
Financial Statements Financial Statements Exhibits
First-in-humans Clinical Trial Force Majeure
Forecasts Forecasts Orders Delivery
Form 10-k Form 10-k Amendment
Form 10-q Further Assurances
General General Administrative Expenses
Governing Law Government Regulation
Grant License Grants Plan-based Awards 2006
Harvey Berger Headings
Householding Annual Disclosure Documents Ide
Identical Counterparts Impairment Long-lived Assets
Income Taxes Ind
Indemnification Ariad Merck Indemnification Expenses Party Wholly Partly Successful
Indemnification Expenses Witness Indemnification Insurance
Indemnification Merck Ariad Indemnification Merck Ariad Ariad8217s Medical Device Collaborators
Indemnification Procedures Indemnity Agreement
Indemnity Proceedings Right Indemnity Third-party Proceedings
Independence Discussions Audit Committees Independent Contractors
Index Infringement Patent Rights
Insufficient Funding Jeopardize Research Development Programs Prevent Commercialization Intangible Other Assets
Intangible Other Assets Net Intellectual Property
Intellectual Property Rights Interest Income Expense
Internally Discovered Drug Candidate Oncology Pipeline Inventory
Investigator Safety Letters Jay Lamarche
John Iuliucci Phd Joint Inventions
Key Corporate Objectives Landsdowne Street Cambridge Massachusetts 02139-4234
Language Laurie Allen Esq
Leases Licensed Technology Other Commitments Legal Officer Secretary
Legal Proceedings Lender
Leukemia Other Hematological Cancers Liability Cap
License Fee License Term
Licensed Field Licensed Patent Rights
Licensed Technology Licenses Parties
Limitations Limited Experience Conducting Clinical Trials Cause Delays Commencing
Limited Experience Manufacturing Product Candidates Raises Uncertainty Ability Liquidity
Liquidity Capital Resources Long-term Debt
Loss Key Members Scientific Management Staff Delay Prevent Maintain Solid Financial Position
Managements Report Internal Control Over Financial Reporting Manufacture Api
Manufacturing Manufacturing Compliance Audits
Market Data Market Information
Market Risk Marketable Securities
Mary Tanner Massimo Radaelli Phd
Master Disclosure Schedule Materials Mailed Stockholders
Matthew Ros Maturity
Maximize Deforolimus Opportunity Maximize Execute Deforolimus Opportunity
Medical Device Medinol
Medinol Data Medinol Indemnity
Medinol Licensed Product Medinol Licensed Product Reports
Medinol Representations Medinol-gore Agreement
Medinols Obligations Meeting Attendance
Membership Michael Kishbauch
Minority Interest Subsidiary Miscellaneous
Mix Direct Compensation Components Modification Waiver
Mutatis Mutandis Name
Narrative Summary Compensation Table Nature Business
Nda Net Sales
Nf- 954 Cell-signaling Technology Nf- 954 Patent Infringement Litigation
Nf-954 Patent Infringement Litigation Nominating Corporate Governance Committee
Nominees Class Directors Term Expire 2010 Non-exclusivity Survival Rights Insurance Subrogation
Non-qualified Deferred Compensation 2006 Non-renewal
Not Able Obtain Government Regulatory Approval Product Candidates Not Able Protect Intellectual Property Relating Research Programs
Not Able Sell Product Candidates Third-party Manufacturers Fail Not Applicable
Notice Annual Meeting Stockholders Held 2007 Notice Infringement
Notices Notification
Now Therefore Objectives Compensation Programs
Officer President Oncogenic Kinase Inhibitor Program
Oncology Indications Mtor Inhibitor Ap23573 Only After
Operating Results Option Exercises Stock Vested 2006
Other Business Other Commitments
Other Data Presented Other Development Progress
Other Events Other Income Tax Refund
Other Information Other Matters Electronic Delivery Stockholder Communications
Other Named Executive Officers Overdue Royalties
Overview Part
Parties Partners Never Succeed Developing Marketable Products Generating Product
Patent Filing Prosecution Maintenance Patent Lawsuit Amgen
Patent Rights Patented Medinol Licensed Product
Payment Payment Royalties Milestones
Payment Royalties Royalty Rates Period Limitations
Permitted Assignee Perquisites
Peter Nelson Phase Clinical Trial Evaluating Same Combination Now Underway
Phase Clinical Trial Ridaforolimus Combined Bevacizumab Solid Tumors Phase Clinical Trial Ridaforolimus Combined Trastuzumab Metastatic Breast
Phase Clinical Trial Underway Evaluate Oral Deforolimus Pivotal Clinical Trial
Pma Policy Applicability
Policy Audit Committee Pre-approval Permissible Non-audit Services Independent Policy Objectives
Policy Respect Director Attendance Annual Meetings Preclinical Data Presented Ariad8217s Investigational Mtor Inhibitor Deforolimus
Preferred Stock Presentation Reminder
Presumptions Effect Certain Proceedings Price Payments
Principles Consolidation Procedure Application Indemnification
Procedure Notification Application Indemnification Product Candidates Not Accepted Patients Physicians Insurers Successful
Product Pipeline Progress Clinic
Project Committee Proof-of-concept Clinical Data Ap24534 Presented Ash
Properties Property Equipment
Proposal Election Class Directors Hold Office Until 2010 Proposal Ratification Selection Independent Registered Public Accounting Firm
Prostate Cancer Provides Update Financial Guidance
Proxies Proxy Properly Executed Voted Directed Herein Undersigned Stockholder
Proxy Solicited Behalf Board Directors Publication
Publicity Purpose
Quantitative Qualitative Disclosures Market Risk Ratification Selection Independent Registered Public Accounting Firm
Raymond Keane Esq Recently Issued Accounting Pronouncements
Registrants Telephone Number Including Area Code 617 494-0400 Registration Process
Regulation Disclosure Regulatory Approval
Regulatory Authority Regulatory Information
Remainder Page Intentionally Left Blank Remedies
Remedies Indemnitee Report Audit Committee
Report Independent Registered Public Accounting Firm Research Development Expenses
Research Development Spending Responsibilities
Restricted Stock Restricted Stock Units Other Equity Awards
Results Dose-ranging Study Support Dose Schedule Selected Ongoing Results Operations Financial Condition
Results Operations General Market Conditions Biotechnology Stocks Result Retained Rights
Revenue Revenue Recognition
Review Royalty Records Reviews Clinical Progress Announces Changes Senior Management Team
Revised Financial Guidance Richard Pascoe
Ridaforolimus Risk Factors
Role Executive Officers Royalty Record Retention
Safety Sale Shares
Sandford Smith Sarcoma
Scientific Approach Scope
Security Security Ownership Certain Beneficial Owners Management
Segment Reporting Selected Quarterly Financial Data
Selection Dose Schedule Phase Trial Senior Vice President
Senior Vice President Chief Senior Vice President Chief Legal Officer Secretary
Services Severability
Signatures Significant Additional Losses Insufficient Funding Cause Default Certain
Solicitation Proxies Sources Funds
Specifications Stent
Stock Appreciation Rights Stock Option Administration
Stock Options Stock Ownership Management Directors Beneficial Owners
Stock Plans Stock-based Compensation
Stockholder Communications Board Directors Stockholder Rights Plan
Stockholders Stockholders Entitled Vote
Stockholders Equity Stockholders Proposals Nominations Director 2008 Annual Meeting
Strengthen Balance Sheet Maintain Solid Financial Position Strong Operational Execution Corporate Objectives Reduced Net Loss
Submission Matters Vote Security Holders Succeed Trial
Succeed Trial Full Enrollment Expected Year-end Succeed Trial Schedule
Summary Compensation Summary Description Non-stockholder Approved Equity Compensation Plan
Supply Agreement Surviving Provisions
Table Contents Tax Withholding Restrictions Payment
Technology Technology Licenses Parties
Term Expiration Term Termination
Termination Bankruptcy Termination Breach
Termination Reason Ariads Material Breach Supply Agreement Termination Reason Material Breach
Timothy Clackson Phd Title
Today8217s Conference Call Reminder Total Direct Compensation Summary
Trademark Transferability
Treasurer Unable Develop Commercialize Product Candidates Obtain Maintain Certain
Unable Establish Sales Marketing Distribution Capabilities Enter Agreements Unpatented Medinol Licensed Product
Upcoming Investor Meeting Upcoming Investor Meetings
Upcoming Investor Partnering Meetings Upcoming Medical Meeting
Upcoming Medical Meetings Uses Funds
Valid Claim Vesting Performance Objectives
Vice President Vote Mail
Vote Phone 1-800-690-6903 Votes Required Broker Non-votes Abstentions
Waiver Wall Street Journal
Warranty Disclaimer Warranty Quality Control Testing
Wayne Wilson Whereas
Witness Whereof Yes
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki